Wall Street Journal : Why Pfizer Will Find It Hard to Appease Its Activist Investor

 

#Business #WallStreet

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Read More  

WSJ.com: US Business  

PAID 

This is a business article located in the U.S. Business section of the Wall Street Journal. For the latest articles on U.S. business, current markets and other business related news follow our Twitter Page or bookmark this website.

Leave a Reply

Generated by Feedzy